# Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/randomized-phase-2-study-of-osimertinib-plus-bevacizumab-versus-osimertinib-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hirotsugu Kenmotsu,Kazushige Wakuda,Keita Mori,Terufumi Kato,Shunichi Sugawara,Keisuke Kirita,Yasuto Yoneshima,Koichi Azuma,Kazumi Nishino,Shunsuke Teraoka,Takehito Shukuya,Ken Masuda,Hidetoshi Hayashi,Ryo Toyozawa,Satoru Miura,Daichi Fujimoto,Kazuhiko Nakagawa,Nobuyuki Yamamoto,Toshiaki Takahashi |
| Citations | 160 |
| DOI | 10.1016/j.jtho.2022.05.006 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jtho.2022.05.006 |
| OpenAlex ID | https://openalex.org/W4281729249 |
| PMID | 35636696 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Keisuke Kirita](https://scholariq.org/researchers/keisuke-kirita/)
- [Daichi Fujimoto](https://scholariq.org/researchers/daichi-fujimoto/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.